Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. has announced the repurchase and cancellation of 276,500 restricted stocks from its third phase incentive plan due to 15 incentive targets no longer meeting the incentive conditions [1][4][11]. Summary by Relevant Sections Announcement of Repurchase - The company held a board meeting on August 20, 2025, where it approved the repurchase of restricted stocks that do not meet incentive conditions, totaling 276,500 shares, which accounts for 0.02% of the company's total share capital [1][4]. - The repurchase includes 174,000 shares from the initial grant and 102,500 shares from the reserved grant [1][4]. Approval Process - The third phase incentive plan underwent necessary approval procedures, including independent opinions from the board and verification by the supervisory board [1][2][3]. - The company disclosed the list of incentive targets and did not receive any objections during the public notice period [2][3]. Repurchase Details - The repurchase price for the initial grant is set at 4.81 yuan per share, while the reserved grant is set at 5.27 yuan per share [4][10]. - The total funds used for the repurchase amount to 1,377,115.00 yuan, sourced from the company's own funds [4][10]. Impact on Company Structure - Following the repurchase, the company's total share capital will decrease by 276,500 shares, with no significant impact on the company's operational performance or management diligence [10][11]. - The total share capital before the repurchase was 1,672,521,258 shares, which will be reduced to 1,672,244,758 shares post-repurchase [10]. Opinions from Committees - The Compensation and Assessment Committee and the Supervisory Board have both expressed their agreement with the repurchase, confirming it aligns with relevant regulations and does not harm the interests of the company or its shareholders [11][11].

证券代码：300009 证券简称：安科生物 公告编号：2025-046 安徽安科生物工程（集团）股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 公司债权人可持证明债权债务关系存在的合同、协议及其他凭证的原件及复 印件到公司申报债权。债权人为法人的，需同时携带法人营业执照副本原件及复 印件、法定代表人身份证明文件；委托他人申报的，除上述文件外，还需携带法 定代表人授权委托书和代理人有效身份证的原件及复印件。债权人为自然人的， 需同时携带有效身份证的原件及复印件；委托他人申报的，除上述文件外，还需 携带授权委托书和代理人有效身份证件的原件及复印件。 一、通知债权人的原因 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 审议通过《关于回购注销部分限制性股票的议案》，同意公司回购注销不符合激 励条件的第三期限制性股票激励计划激励对象已获授但尚未解除限售的 276,500 股限制性股票。具体内容详见刊登在中国证监会指定信息披露网站巨潮资讯网的 《关于回购注销第三期限制性股票激励计划部分限制性股票的公告》 （公告编号： 本次限制性股票回 ...

安科生物8月21日披露半年报，公司上半年实现营业收入12.92亿元，同比下降0.51%；归属于上市公司 股东的净利润3.67亿元，上年同期4.16亿元，同比下降11.92%；基本每股收益0.2191元。 ...

Core Viewpoint - The report highlights the financial performance and strategic positioning of Anhui Anke Biotechnology Group Co., Ltd. during the first half of 2025, emphasizing the company's focus on innovation in the biopharmaceutical sector and its response to market demands and regulatory changes [1][3]. Financial Performance - The company reported a revenue of approximately 1.29 billion yuan, a decrease of 0.51% compared to the previous year [2][16]. - The net profit attributable to shareholders was approximately 366.5 million yuan, reflecting a decline of 11.92% year-on-year [2][16]. - The basic earnings per share decreased by 11.72% to 0.2191 yuan [2][16]. - Total assets at the end of the reporting period were approximately 4.92 billion yuan, down 4.14% from the previous year [2][16]. Industry Overview - The biopharmaceutical industry is recognized as a strategic emerging industry in China, with significant growth potential driven by technological advancements and an aging population [3][4]. - The global biopharmaceutical market is projected to reach 1.71 trillion USD by 2025, with China leading the growth at a compound annual growth rate (CAGR) of 14.5% [3][4]. - The industry is undergoing a transformation towards precision, intelligence, and innovation, supported by favorable government policies [3][4]. Company Positioning - The company is positioned as a national high-tech enterprise with strong independent innovation capabilities, having undertaken numerous national and provincial projects [3][4]. - It has achieved significant milestones, including the commercialization of the first domestic human interferon α2b and the launch of various innovative drugs [3][4]. - The company is actively expanding its product pipeline, focusing on monoclonal antibodies, bispecific antibodies, and innovative ADC drugs [3][4]. Business Segments - The main business includes the research, development, production, and sales of biopharmaceuticals, with a focus on gene-engineered drugs and biological diagnostic reagents [5][6]. - The company has successfully launched new products, such as the Acetate Atosiban injection, enhancing its competitive position in the assisted reproductive medicine market [5][6]. - The product portfolio includes human interferon α2b, human growth hormone, and various traditional Chinese medicine products, catering to a wide range of medical needs [5][6]. Strategic Initiatives - The company is committed to enhancing its core competitiveness by accelerating the R&D and commercialization of innovative drugs [5][6]. - It aims to strengthen collaborations with domestic and international research institutions and enterprises to drive technological innovation [5][6]. - The company is focused on optimizing its business structure and expanding market channels to improve operational efficiency and overall business growth [5][6].

Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. reported a slight decline in revenue and net profit for the first half of 2025, while showing significant growth in cash flow from operating activities and a strong performance in its main business of biological products, particularly in the reproductive health sector [1][3]. Financial Performance - The company's operating income for the reporting period was approximately 1.29 billion yuan, a decrease of 0.51% compared to the same period last year [1]. - The net profit attributable to shareholders was approximately 366.52 million yuan, down 11.92% year-on-year [1]. - The net cash flow from operating activities increased by 53.75% to approximately 316.42 million yuan [1]. - Basic earnings per share decreased by 11.72% to 0.2191 yuan [1]. Asset and Equity Status - Total assets at the end of the reporting period were approximately 4.92 billion yuan, a decrease of 4.14% from the previous year [2]. - The net assets attributable to shareholders were approximately 3.97 billion yuan, down 3.73% year-on-year [2]. Shareholder Structure - The top shareholder, Song Lihua, holds 26.56% of the shares, followed by Song Liming with 6.87% [2]. - The company has not experienced any changes in its controlling shareholder during the reporting period [3]. Business Development and Strategy - The company has optimized its sales channels and marketing strategies in response to intensified industry competition and market demand fluctuations, resulting in a 7.49% year-on-year growth in its main business of biological products [3]. - Sales revenue from the injectable drug Trastuzumab "Ansaiting" increased by 298% year-on-year [3]. - The company signed a strategic cooperation framework agreement with Weisheng Pharmaceutical to collaborate on a growth hormone product, enhancing its market position in the pediatric growth sector [4]. R&D and Product Pipeline - The company is advancing its R&D capabilities, with several projects in various clinical trial phases, including the HuA21 project and AK2017 injection [6][10]. - The company has received approval for the launch of Acetate Atosiban Injection, expanding its product offerings in the peptide formulation sector [7]. - The company is also developing mRNA vaccines in collaboration with Afana, with progress in clinical trials for HPV-related conditions [8][9]. Production Capacity and Infrastructure - The company is constructing a new production base in the eastern region, with approximately 90,000 square meters of infrastructure completed [4]. - New production lines for growth hormone injections and Trastuzumab have received production licenses and are in the registration and review stages [4][6].

Core Points - The company held its 21st meeting of the 8th Board of Directors on August 20, 2025, with all 12 directors present, confirming compliance with legal and regulatory requirements [1][2] - The board approved the 2025 semi-annual report and its summary, which will be published on designated information disclosure websites [1][2] - The board also approved the repurchase and cancellation of 276,500 restricted stocks that do not meet incentive conditions, representing 0.02% of the company's total share capital [2]

证券代码：300009 证券简称：安科生物 公告编号：2025-046 安徽安科生物工程（集团）股份有限公司 关于回购注销部分限制性股票减资暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、通知债权人的原因 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开的第八届董事会第二十一次会议、第八届监事会第十九次会议， 审议通过《关于回购注销部分限制性股票的议案》，同意公司回购注销不符合激 励条件的第三期限制性股票激励计划激励对象已获授但尚未解除限售的 276,500 股限制性股票。具体内容详见刊登在中国证监会指定信息披露网站巨潮资讯网的 《关于回购注销第三期限制性股票激励计划部分限制性股票的公告》（公告编号： 2025-045）。 本次限制性股票回购注销完成后，将导致公司股本总额减少 276,500 股、公 司注册资本减少 276,500.00 元。股本变动情况以回购注销事项完成后中国证券登 记结算有限公司深圳分公司出具的股本结构表为准，公司董事会将根据深圳证券 交易所与中国证券登记结算有限公司深圳分公 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-045 安徽安科生物工程（集团）股份有限公司 关于回购注销第三期限制性股票激励计划 部分限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于2025年8 月20日召开第八届董事会第二十一次会议审议通过了《关于回购注销部分限制性 股票的议案》，根据公司2022年第二次临时股东大会的授权，同意回购注销不符 合激励条件的公司第三期限制性股票激励计划（以下简称"第三期激励计划"） 激励对象已获授但尚未解除限售的全部限制性股票，本次回购注销限制性股票合 计276,500股，占公司现有总股本的0.02%，其中：首次授予部分限制性股票回购 注销数量为174,000股，预留授予部分限制性股票回购注销数量为102,500股。 现就有关事项说明如下： 一、第三期激励计划已履行的相关审批程序 1、2022 年 8 月 24 日，公司召开第七届董事会第二十二次会议及第七届监 事会第十九次会议，审议通过了《关于<公司第三期限制性股票激励计划（草 ...

安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 第三期限制性股票激励计划 回购注销部分限制性股票相关事项 安徽天禾律师事务所 法律意见书 之 法律意见书 致：安徽安科生物工程（集团）股份有限公司 安徽天禾律师事务所（以下简称"本所"）接受安徽安科生物工程（集团） 股份有限公司（以下简称"安科生物"或"公司"）的委托，担任安科生物实 施第三期限制性股票激励计划相关事宜（以下简称"本次股权激励计划"或"激 励计划"）的专项法律顾问。本所律师根据《中华人民共和国公司法》（以下 简称《公司法》）《上市公司股权激励管理办法》（证监会 148 号令）（以下 简称《管理办法》）《深圳证券交易所创业板股票上市规则》（以下简称《上 市规则》）《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》等有关法律及其他有关法律、法规、规范性文件，以及《安徽安科生物工 程（集团）股份有限公司第三期限制性股票激励计划（草案）》（以下简称《激 励计划》）和《安徽安科生物工程（集团）股份有限公司公司章程》（以下简 称《公司章程》）的相关规定，对本次股权激励计划所涉及的回购注销部分限 制性股票相关事项出具本法律意见 ...

安徽安科生物工程（集团）股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：安徽安科生物工程（集团）股份有限公司 单位：元 | 占用方与上 | 上市公司核 | 年 | 月 | 年 | 月 | 2025 | 1-6 | 2025 | 1-6 | 非经营性资金 | 年初占 | 年 | 月偿 | 年 | 月末 | 占用形成 | 2025 | 2025 | 1-6 | 2025 | 6 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用方名称 | 市公司的关 | 算的会计科 | 往来累计发生 | 往来资金的 | 占用性质 | 占用 | 用资金余额 | 还累计发生金额 | 往来资金余额 | 原因 | | | | | | | | | | | | | 联关系 | 目 | 金额(不含利息) | 利息(如有) | | | | | | | | | | | | ...